Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ATHENE study results support the benefit of NeuroAiD™II (MLC901) as a safe add-on therapy to standard AD treatment as the study found no evidence of a significant increase in adverse events between MLC901 and placebo.
Lead Product(s): MLC901
Therapeutic Area: Neurology Product Name: NeuroAiD II
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National University Hospital Singapore
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2022